Brief: Hemostemix Announces Milestone Achieved With First 3 U.S. Trial Sites For Phase II Clinical Trial Open For Patient Enrollment
30/05/2018 13:37
May 30 (Reuters) - Hemostemix Inc HEM.V :
* HEMOSTEMIX ANNOUNCES MAJOR MILESTONE ACHIEVED WITH FIRST 3
U.S.
TRIAL SITES FOR PHASE II CLINICAL TRIAL OPEN FOR PATIENT
ENROLLMENT
Source text for Eikon: ID:nGNX3MGXv4
Further company coverage: HEM.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hemostemix
See all newsBrief: Hemostemix Announces Financing Update And Secured Convertible Debenture Financing Of Up To $2,000,000
Brief: Aspire Health Science Files Supplemental Motion For Expedited Hearing In Lawsuit Against Hemostemix Inc. And Suspends Patient Recruitment For Hemostemix Cli Phase 2 Clinical Trial
Brief: Aspire Health Sciences Says On Jan 28, 2020, Initiated Legal Proceeding Against Hemostemix Inc
Brief: Hemostemix Announces Private Placement
Brief: Hemostemix Announces Corporate Update